Posted by Michael Wonder on 22 Oct 2025
Immusoft receives FDA fast track designation for ISP-001, a first in class engineered B-cell therapy for MPS I
21 October 2025 - Prospectively designed for scalability and re-dosability, Immusoft's engineered B cells represent the next generation of advanced therapeutics.
Immusoft today announced that the US FDA has granted fast track designation to ISP-001, the Company's lead investigational therapy for the treatment of mucopolysaccharidosis type I, a rare and life-threatening lysosomal storage disorder.
